Related Experiment Video

Updated: Jun 19, 2025

Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors
10:17

Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors

Published on: October 9, 2016

15.2K

Recalcitrant Folliculitis Decalvans Treatment Outcomes With Biologics and Small Molecule Inhibitors

Tamara Fakhoury1, Katelyn Urban1, Leila Ettefagh1

  • 1Dr. Fakhoury is from Lake Erie College of Osteopathic Medicine, Bradenton, Florida. Dr. Urban is from Prime West Consortium, Newport Beach, California. Drs. Ettefagh and Nami are from Island Dermatology, Newport Beach.

Cutis
|July 23, 2024
PubMed

Insights

Folliculitis decalvans (FD) is a rare scarring alopecia resistant to standard treatments. This review analyzes newer therapies like biologics and small molecule inhibitors for difficult-to-treat cases.

Area of Science:

  • Dermatology
  • Trichology
  • Inflammatory Alopecia

Background:

  • Folliculitis decalvans (FD) is a rare neutrophilic cicatricial alopecia.
  • FD often proves resistant to conventional therapeutic approaches.
  • Limited evidence exists for managing therapy-recalcitrant FD.

Purpose of the Study:

  • To systematically review emerging treatments for recalcitrant Folliculitis decalvans.
  • To analyze the efficacy of biologics, small molecule inhibitors, and other targeted therapies.

Main Methods:

  • Systematic literature review.
  • Analysis of studies investigating biologics, TNF inhibitors, JAK inhibitors, PDE4 inhibitors, and monoclonal antibodies.
  • Focus on treatments for therapy-resistant Folliculitis decalvans.

Main Results:

  • Identified various targeted therapies showing promise for recalcitrant FD.
  • Summarized data on biologics, small molecule inhibitors, and immunomodulators.
  • Highlighted the need for further research on optimal treatment strategies.

Conclusions:

  • Novel therapeutic agents offer potential for managing treatment-resistant Folliculitis decalvans.
  • Biologics and small molecule inhibitors represent promising avenues.
  • Further investigation is warranted to establish definitive treatment guidelines for recalcitrant FD.

More Related Videos

Assessing Biofilm Dispersal in Murine Wounds12:18

Assessing Biofilm Dispersal in Murine Wounds

Published on: August 7, 2021

4.3K
Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth11:06

Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth

Published on: April 23, 2019

7.8K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
126
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134